Skip to main content
SpringerLink
Log in

Prediction of the antitumor activity of new platinum analogs based on their ex vivo pharmacodynamics as determined by bioassay

  • Original Articles
  • Antitumor Activity, Platinum Analogs, Pharmacodynamics
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Summary

We report the predictive model for the clinical response of new platinum analogs against lung cancer by a bioassay using human lung-cancer cell lines including small-cell (SCLC) and non-small-cell lung cancer (NSCLC). Exponentially growing cells of six different SCLC and sic NSCLC lines were exposed to different concentrations of the three platinum compounds, cisplatin, carboplatin, and 254-S in a double-agar colony-forming cell assay. The concentrations inhibiting 50% of colony formation (IC50 value) for cisplatin, carboplatin and 254-S in SCLC cell lines were significantly lower than those in NSCLC cell lines. A total of 15 patients entered the pharmacological study. In all, 80 mg/m2 cisplatin, 450 mg/m2 carboplatin, and 100 mg/m2 254-S were each given to five patients by intravenous drip infusion. Bioassay as well as chemical assay was achieved by clonogenic techniques using NCI-H-69 (SCLC cell line) and PC-9 (NSCLC cell line) as target cells. Biological comparison of antitumor activity was performed on the basis of the antitumor activity of patients' plasma using the antitumor index (ATI), which was defined as the area under the percentage of colony suppression versus time curve obtained by bioassay and calculated by the trapezoidal rule. When NCI-H-69 and PC-9 were used as target cells for bioassay, colony-inhibitory activity was revealed by the ATIs. The ATIs obtained by bioassay showed better correlation than the AUCs obtained by chemical assay with the clinical response for cisplatin and carboplatin against SCLC and NSCLC, according to the following equation: [Reported Response (%)]=11.5668+0.0014×[ATI] (r=0.97). The response rates for 254-S against SCLC and NSCLC were predicted by this formula to be 40%–65% and 14%–16%, respectively. 254-S is prospectively suspected of having the same, if not more, activity then carboplatin against SCLC and of having almost the same activity as cisplatin against NSCLC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Aisner J (1987) Identification of new drugs in small cell lung cancer: phase II agants first? (1987) Cancer Treat Rep 71: 1131

    Google Scholar 

  2. Ariyoshi Y, Fujii M, Kurita Y, Ohshima S, Tamura M, Inoue S, Nishiwaki Y, Kimura I, Niitani H (1989) Phase II clinical study of (glycolato-0,0′)-diammineplatinum(II) (254-S), a new platinum complex, for primary lung cancer. Proc Am Soc Clin Oncol 8: 927

    Google Scholar 

  3. Bruckner HW, Cohen CJ, Gusberg SB, Wallach RC, Kabakow B, Greenspan EM, Holland JF (1976) Chemotherapy of ovarian cancer with Adriamycin (ADM) and cisplatinum (DDP). Proc Am Soc Clin Oncol 17: 287

    Google Scholar 

  4. Carmichael J, Mitchell JB, DeGraff WG, Gamson J, Gazdar AF, Johnson BE, Glatstein E, Minna JD (1988) Chemosensitivity testing of human lung cancer cell lines using the MTT assay. Br J Cancer 57: 540

    Google Scholar 

  5. Carney DN, Gazdar AF, Bepler G, Guccion JG, Marangos PJ, Moody TW, Zweig MH, Minna JD (1985) Establishment and identification of small cell lung cancer cell lines having classic and variant features. Cancer Res 45: 2913

    Google Scholar 

  6. Casper ES, Gralla RJ, Kelson DP, Cvitkovic E, Golbey RB (1979) Phase II study of high-dosecis-dichlorodiammineplatinum(II) in the treatment of non-small-cell lung cancer. Cancer Treat Rep 63: 2107

    Google Scholar 

  7. Cavalli F, Jungi WF, Sonntag RW, Nissen NI, Holland JF (1979) Phase II trial ofcis-dichlorodiammineplatinum(II) in advanced malignant lymphoma and small-cell lung cancer: preliminary results. Cancer Treat Rep 63: 1599

    Google Scholar 

  8. Cavalli F, Goldhirsch A, Sigenthaler P, Kaplan S, Beer M (1980) Phase II study withcis-dichlorodiammineplatinum(II) in small-cell anaplastic bronchogenic carcicnoma. Eur J Cancer 16: 617

    Google Scholar 

  9. Creekmore SP, Micetich KC, Vogelzang N, Canzoneri C, Choudhury A, Fisher RI (1985) Low toxicity and significant tumor responses in phase II trials of carboplatin (CBDCA) in head and neck, non-small-cell lung, urotherial and ovarian cancers Proc Am Soc Clin Oncol 4: 144

    Google Scholar 

  10. Dombernowsky P, Sorenson S, Aisner J, Hoi H (1979)cis-Dichlorodiammineplatinum(II) in small-cell anaplastic bronchogenic carcinoma: a phase II study. Cancer Treat Rep 63: 543

    Google Scholar 

  11. Egorin MJ, Van Echo DA, Tippin SJ, Olman EA, Whitacre MY, Thompson BW, Aisner J (1984) Pharmacokinetics and dosage reduction ofcis-diammine(1,1-cyclobutanedecarboxylato)platinum in patients with impaired renal function. Cancer Res 44: 5432

    Google Scholar 

  12. Einhjorn LH, Donohue J (1977)cis-Diamminedichloroplatinum, vinblastine and bleomycin combination chemotherapy in disseminated testicular cancer. Ann Intern Med 87: 293

    Google Scholar 

  13. Fujita J, Saijo N, Eguchi K, Shimizu E, Shinkai T, Tominaga K, Sasaki Y, Futami H, Sakurai M, Hoshi A (1985) A phase II study ofcis-diamminedichloroplatinum in patients with non-small-cell lung cancer. Jpn J Cancer Res 76: 420

    Google Scholar 

  14. Gralla RJ, Cvitkovi E, Golbey RB (1979)cis-Dichlorodiammineplatinum(II) in non-small-cell carcinoma of the lung. Cancer Treat Rep 63: 1585

    Google Scholar 

  15. Hamburger AW, Salmon SE (1977) Primary bioassay of human tumor stem cells. Science 197: 461

    Google Scholar 

  16. Hayata Y, Tsuji K (1975) Lung cancer. In: Ohboshi S, Sugano H (eds) Culture of human cancer cells (in Japanese). Asakurashoten, Tokyo, p 131

    Google Scholar 

  17. Jager R de, Longeval E, Klastersky J (1980) High-dose cisplatin with fluid and mannitol-induced diuresis in advanced lung cancer: a phase II clinical trial of the EORTC lung cancer working party (Belgium). Cancer Treat Rep 64: 1341

    Google Scholar 

  18. Kreisman H, Ginsberg S, Propert KJ, Richards F, Graziano S, Green M (1987) Carboplatin or iproplatin in advanced non-small-cell lung cancer: a cancer and leukemia group B study. Cancer Treat Rep 71: 1049

    Google Scholar 

  19. Lathan B, Clark GM, Von Hoff DD (1985) In vitro comparison of vinzolidine and vinblastine: a model for methods of evaluation of analogues in a human tumor cloning system. Cancer Res 45: 6286

    Google Scholar 

  20. Leroy AF, Mehling ML, Sponseller HL (1977) Analysis of platinum in biological materials by flameless atomic absorption spectrophotometry. Biochem Med 18: 184

    Google Scholar 

  21. Levenson RM Jr, Ijde DC, Huberman MS, Cohen MH, Bunn PA, Minna JD (1981) Phase II trial of cisplatin in small-cel carcinoma of the lung. Cancer Treat Rep 65: 905

    Google Scholar 

  22. Olver IN, Donehower RC, Van Echo DA, Ettinger DS, Aisner J (1986) Phase II trial of carboplatin in non-small-cell lung cancer. Cancer Treat Rep 70: 421

    Google Scholar 

  23. Panettiere FJ, Vance RB, Stuckey WJ, Coltman CA Jr, Costanzi JJ, Chen TT (1983) Evaluation of single-agent cisplatin in the management of non-small-cell carcinoma of the lung: a Southwest Oncology Group study. Cancer Treat Rep 67: 399

    Google Scholar 

  24. Rosenberg B, Van Camp L, Trosko JE, Masour VH (1969) Platinum compounds: a new class of potent antitumor agents. Nature 222: 385

    Google Scholar 

  25. Rossof AH, Bearden JD III, Coltman CA Jr (1976) Phase II evaluation ofcis-diamminedichloroplatinum(II) in lung cancer. Cancer Treat Rep 601: 1679

    Google Scholar 

  26. Salmon SE (1984) Human tumor colony assay and chemosensitivity testing. Cancer Treat Rep 68: 117

    Google Scholar 

  27. Sasaki Y, Saijo N, Lee JY, Takahashi H, Ishihara J, Sakurai M, Sano T, Nakano H, Kanzawa F, Hoshi A, Hamburger AW (1986) A bioassay of cisplatin by human tumor clonogenic assay. Jpn J Cancer Res 77: 494

    Google Scholar 

  28. Sasaki Y, Tamura T, Eguchi K, Shinkai T, Fujiwara Y, Fukuda M, Ohe Y, Bungo M, Horichi N, Niimi S, Minato K, Nakagawa K, Saijo N (1989) Pharmacokinetics of (glycolato-O,O')-diammineplatinum(II), a new platinum derivative, in comparison with cisplatin and carboplatin. Cancer Chemother Pharmacol 23: 234

    Google Scholar 

  29. Sasaki Y, Fukuda M, Morita M, Shinkai T, Eguchi K, Tamura T, Ohe Y, Yamada K, Kojima A, Nakagawa K, Saijo N (1990) Prediction by creatinine clearance of thrombocytopenia and recommended dose in patients receiving (glycolato-O,O')-diammineplatinum(II) (NSC 375101D). Jpn J Cancer Res 81: 196

    Google Scholar 

  30. Scheithauer W, Clark GM, Moyer MP, Von Hoff DD (1986) New screening system for selection of anticancer drugs for treatment of human colorectal cancer. Cancer Res 46: 2703

    Google Scholar 

  31. Scheithauer W, Moyer MP, Clark GM, Von Hoff DD (1988) Application of a new preclinical drug screening system for cancer of the large bowel. Cancer Chemother Pharmacol 21: 31

    Google Scholar 

  32. Shinkai T, Saijo N, Tominaga, K, Eguchi K, Shimizu E, Sasaki Y, Fujita J, Futami H (1985) Comparison of vindesine plus cisplatin or vindesine plus mitomycin in the treatment of advanced non-small-cell lung cancer. Cancer Treat Rep 69: 945

    Google Scholar 

  33. Shiratori O, Kanai H, Uchida N, Takeda Y, Totani T, Sato K (1985) Antitumor activity of 254-S, a platinum complex, in rodents. In: Ishigami J (ed) Recent advances in chemotherapy, anticancer section 1. University of Tokyo Press, Tokyo, p 635

    Google Scholar 

  34. Smith IE, Harland SJ, Robinson BA, Evans BD, Goodhart LC, Calvert AH, Yanold J, Gleees JP, Baker J, Ford HT (1985) Carboplatin: a very active new cisplatin analog in the treatment of small-cell lung cancer. Cancer Treat Rep 69: 43

    Google Scholar 

  35. Soloway MS (1978) cis-Diamminedichloroplatinum(II) in advanced bladder cancer. J urol 120: 716

    Google Scholar 

  36. Takahashi K, Seki T, Nishikawa K, Minamide S, Iwabuchi M, Ono M, Nagamine S, Horinishi H (1985) Antitumor activity and toxicity of serum protein-bound platinum formed from cisplatin. Jpn J Cancer Res 76: 68

    Google Scholar 

  37. Tamura T, Saijo N, Shinkai T, Eguchi K, Sasaki Y, Sakurai M, Fujiwara Y, Nakano H, Nakagawa K, Minato K, Hong WS (1988) Phase II study of carboplatin in small-cell lung cancer. Jpn J Clin Oncol 18: 27

    Google Scholar 

  38. Tamura T, Shinkai T, Eguchi K, Sasaki Y, Fujiwara Y, Fukuda M, Ohe Y, Nakagawa K, Minato K, Saijo N (1989) Phase II study of carboplatin in non-small-cell lung cancer. Jpn J Oncol 19: 51

    Google Scholar 

  39. Terasaki T, Kameya T, Nakajima T, Tsumuraya M, Shimosato Y, Kato K, Ichinose H, Nagatsu T (1984) Interconversion of biological characterstics of small-cell lung cancer depending on culture conditions. Jpn J Cancer Res 75: 1089

    Google Scholar 

  40. Vugrin D, Herr HW, Whitemore WF Jr, Sogani PC, Golbey RB (1981) VAB-6 combination chemotherapy in disseminated cancer of the testis. Ann Intern Med 95: 59

    Google Scholar 

  41. Wilkinson R, Cox PJ, Jones M, Harrap KR (1978) Selection of potential second generation platinum compound. Biochemie 60: 851

    Google Scholar 

  42. William CR, John ES (1985) Preclinical antitumor and toxicologic profile of carboplatin. Cancer Treat Rev 12 [Suppl A]: 1

    Google Scholar 

  43. Wiltshaw E (1976) Phase II study ofcis-dichlorodiammineplatinum(II) (NSC-119875, CACP) in advanced adenocarcinoma of the ovary. Cancer Treat Rep 60: 55

    Google Scholar 

  44. Yagoda A, Watson RC, Kemeny N, Barzell WE, Grabstrald H, Whitemore WF (1978) Diamminedichloride platinum II and cyclophosphamide in the treatment of advanced urothelial cancer. Cancer 41: 2121

    Google Scholar 

  45. Yamaoka K, Tanigawara Y, Nakagawa T, Uno T (1980) Pharmacokinetic analysis program (MULTI) for microcomputer. J Pharm Dyn 4: 879

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology, National Cancer Center, 1-1, Tsukiji 5-Chome, Chuo-ku, 104, Tokyo, Japan

    Yasutsuna Sasaki, Tetsu Shinkai, Kenji Eguchi, Tomohide Tamura & Yuichiro Ohe

  2. Pharmacology Division, National Cancer Center, 1-1, Tsukiji 5-Chome, Chuo-ku, 104, Tokyo, Japan

    Tohru Ohmori & Nagahiro Saijo

Authors
  1. Yasutsuna Sasaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tetsu Shinkai
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kenji Eguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Tomohide Tamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yuichiro Ohe
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Tohru Ohmori
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Nagahiro Saijo
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

This work was supported in part by a Grant-in-Aid for Cancer Research and for the Comprehensive 10-year strategy for Cancer Control from the Ministry of Health and Welfare and by grants from the Foundation for the Promotion of Cancer Research

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sasaki, Y., Shinkai, T., Eguchi, K. et al. Prediction of the antitumor activity of new platinum analogs based on their ex vivo pharmacodynamics as determined by bioassay. Cancer Chemother. Pharmacol. 27, 263–270 (1991). https://doi.org/10.1007/BF00685110

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00685110

Keywords

Search

Navigation